RE: SPAC17 Jan 2021 12:22
Hi RF Investments,
Thanks for this article.
Presciently (written in 2018) it warns that.."Furthermore, in the past few decades, animal influenza viruses, such as avian influenza A virus subtypes H5N1 and H7N9, have caused sporadic human infections and deaths [5]. These viruses, termed “prepandemic influenza viruses,” are acquired through close contact with infected animals but do not demonstrate sustained person-to-person spread. However, there is global concern that viral mutations may allow efficient transmission among humans and lead to the next influenza pandemic...."
Of more relevance to ORPH today, amongst other things it makes the case for human challenge studies (re influenza) :
.." Influenza challenge trials in healthy human volunteers may overcome certain of these limitations and offer a unique opportunity to ask focused questions regarding influenza virus pathogenesis and vaccine efficacy in a controlled manner. The following activities will address these gaps:
Increase the number of sites capable of performing human challenge studies.
Optimize and standardize available influenza virus challenge strains, disease models, and infection methods.
Use the human challenge model to address questions related to influenza virus pathogenesis, immunity, and correlates of protection.
Evaluate next-generation universal influenza vaccine candidates in healthy volunteers for downselection by comparing them to the best available conventional vaccines.
Compare data from human challenge studies to data from studies of natural infection...."
ORPH really does seem to be in the 'sweet spot ' at the moment .
ATB
Sign In
Follow the stocks
